Spectrum’s Shrotriya Says Sales Will Match or Beat the Previous Quarter’s

Spectrum Pharmaceuticals Inc. (SPPI)’s fourth-quarter sales will match or beat the previous quarter’s revenue, Chief Executive Officer Rajesh Shrotriya said.

“We will maintain our revenue, the same or better” than Spectrum’s third-quarter sales of $51 million, Shrotriya said today in a telephone interview.

Spectrum, of Irvine, California, declined 6.6 percent to $14 at 1:49 p.m. New York time in the biggest intraday drop since Dec. 9. “Rumor and perception” that the company’s fourth-quarter revenue will fall short of third-quarter sales may have caused the decline, he said.

The company’s stock has had a “tremendous run” in the past year, and “we’re not hearing anything that would have us worry that it’s being derailed,” Reni Benjamin, an analyst with Rodman & Renshaw in New York, said today by telephone. The shares had more than doubled in the year before today.

To contact the reporter on this story: Molly Peterson in Washington at mpeterson9@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.